PMID- 34328359
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20230916
IS  - 1532-2750 (Electronic)
IS  - 1098-612X (Print)
IS  - 1098-612X (Linking)
VI  - 24
IP  - 6
DP  - 2022 Jun
TI  - Field safety experience with an autologous cancer vaccine in tumor-bearing cats: 
      a retrospective study of 117 cases (2015-2020).
PG  - 493-499
LID - 10.1177/1098612X211031504 [doi]
AB  - OBJECTIVES: The aim of this study was to determine the frequency and severity of 
      adverse events (AEs) reported from use of an adjuvanted whole-cell autologous 
      cancer vaccine in cats with solid tumors under field conditions. METHODS: The 
      case accession database at Torigen Pharmaceuticals was searched to identify 
      client-owned cats that underwent biopsy or surgical resection of their primary 
      tumor, had histologic confirmation of neoplasia and received at least one 
      subcutaneous dose of an adjuvanted whole-cell autologous cancer vaccine. Records 
      were reviewed for any reported AEs. RESULTS: In total, 117 cats met the inclusion 
      criteria and received 422 doses of autologous cancer vaccine. Six (5.1%) cats had 
      seven reported AEs, with the majority of these (85.7%) being characterized as 
      grade 1 or 2 (mild) and resolving without medical intervention. CONCLUSIONS AND 
      RELEVANCE: AEs were infrequent in cats treated with an adjuvanted whole-cell 
      autologous cancer vaccine under typical field use conditions. This form of active 
      cancer immunotherapy appears to be well tolerated by cats and may represent a 
      treatment option for owners who are concerned about AEs associated with 
      chemotherapy or radiotherapy. Additional studies are warranted to determine the 
      efficacy of this form of individualized immunotherapy in cats with solid tumors.
FAU - Lucroy, Michael D
AU  - Lucroy MD
AUID- ORCID: 0000-0002-1166-4991
AD  - Torigen Pharmaceuticals, Farmington, CT, USA.
FAU - Kugler, Alexa M
AU  - Kugler AM
AD  - Torigen Pharmaceuticals, Farmington, CT, USA.
FAU - El-Tayyeb, Ferris
AU  - El-Tayyeb F
AD  - Torigen Pharmaceuticals, Farmington, CT, USA.
FAU - Clauson, Ryan M
AU  - Clauson RM
AD  - Torigen Pharmaceuticals, Farmington, CT, USA.
FAU - Kalinauskas, Ashley E
AU  - Kalinauskas AE
AD  - Torigen Pharmaceuticals, Farmington, CT, USA.
FAU - Suckow, Mark A
AU  - Suckow MA
AD  - The Office of the Vice President for Research, University of Kentucky, Lexington, 
      KY, USA.
LA  - eng
PT  - Journal Article
DEP - 20210730
PL  - England
TA  - J Feline Med Surg
JT  - Journal of feline medicine and surgery
JID - 100897329
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Veterinary Drugs)
SB  - IM
MH  - Adjuvants, Immunologic/adverse effects
MH  - Animals
MH  - *Cancer Vaccines/adverse effects
MH  - *Cat Diseases/drug therapy
MH  - Cats
MH  - *Neoplasms/drug therapy/veterinary
MH  - Retrospective Studies
MH  - *Veterinary Drugs
PMC - PMC9160946
OTO - NOTNLM
OT  - Autologous cancer vaccine
OT  - cancer
OT  - cancer immunotherapy
OT  - safety
COIS- Conflict of interest: The authors declared no potential conflicts of interest 
      with respect to the research, authorship, and/or publication of this article.
EDAT- 2021/07/31 06:00
MHDA- 2022/06/03 06:00
PMCR- 2022/06/02
CRDT- 2021/07/30 12:13
PHST- 2021/07/31 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
PHST- 2021/07/30 12:13 [entrez]
PHST- 2022/06/02 00:00 [pmc-release]
AID - 10.1177_1098612X211031504 [pii]
AID - 10.1177/1098612X211031504 [doi]
PST - ppublish
SO  - J Feline Med Surg. 2022 Jun;24(6):493-499. doi: 10.1177/1098612X211031504. Epub 
      2021 Jul 30.